Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group
TAIPEI, Dec. 15, 2025 /PRNewswire/ -- Leadgene Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development with integrated CRO/CDMO services. This alignment enables the combined organization to offer a full suite of bioprocessing products, solutions, and services...
Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational GalNAc-conjugated siRNA targeting INHBE for obesity treatment. Cohort 1 was completed successfully with a favorable initial...
Curie Oncology and Oncoshot Deploy AI to Improve Patient Outcomes in Asia
SINGAPORE, Dec. 15, 2025 /PRNewswire/ -- Curie Oncology, one of Southeast Asia's fastest-growing private oncology networks, has partnered with Singapore-based health-tech company Oncoshot to deploy AI-powered clinical research tools that help patients gain faster access to clinical trials. From left to right: Ruslan Enikeev, CTO and cofounder of Oncoshot; Adrian Chan, integration project manager...
Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease
SHANGHAI and HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application to initiate global Phase Ⅲ clinical trials of MHB018A for the treatment of thyroid eye disease (TED). The...
MEDEZE Receives Frost & Sullivan’s 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine
The company is revolutionizing regenerative healthcare through innovation, clinical alignment, and GMP-grade excellence across Southeast Asia SAN ANTONIO, Dec. 15, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to announce that MEDEZE Group Public Company Limited (MEDEZE) has been honored with the 2025 Southeast Asia Company of the Year Recognition in the stem cell banking and regenerative medicine industry for its outstanding...
Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
- The elimination half-life of ASC50 after a single oral dose was 43, 89, 91, 87, 104, and 85 hours for 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg, respectively, supporting once-daily or potentially once-weekly oral dosing. - ASC50 had strong target engagement after a single oral dose, indicated by elevated plasma interleukin-17A...
Global Spotlight｜POGMENT Biomimetic Collagen “Stable Triple Helix” Breakthrough Stuns the World–Extraordinary and Breathtaking
CHENGDU, China, Dec. 15, 2025 /PRNewswire/ -- Recently, LivingPhoenix Regenerative Technologies has captured widespread attention with its world-first "Stable Triple-Helix Biomimetic Collagen" technology, making consecutive appearances at 12 high-level academic conferences in November. These events spanned aesthetic medicine, regenerative medicine, and personal care. Several academicians and industry experts have unanimously hailed the innovation as a mark of collagen R&D's...
Medit Announces 2025 Year-End Promotion
SEOUL, South Korea, Dec. 15, 2025 /PRNewswire/ -- Medit, a global leader in 3D dental scanning solutions, announced the launch of "Medit's 2025 End of Year Promotion," a limited-time campaign delivering significant benefits to dental professionals worldwide. Dental professionals can learn more about the promotion details and encourage to leave their contact...
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial, which has recruited and dosed its target 286th adult patient The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood pressure medication over 2 years Of the 286 adult patients dosed in the trial, 69 have...
Viva Biotech’s invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value,...
